ArticleThe Journal of clinical psychiatry2013
Substance-induced psychoses converting into schizophrenia: a register-based study of 18,478 Finnish inpatient cases.
Article in The Journal of clinical psychiatry, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 69 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
69 citing papers in PubMed, 4 syntheses or guidelines pooled it.
- Prevalence of schizophrenia spectrum and bipolar disorder among patients with cannabis induced psychosis: a systematic review and meta-analysis.BMC psychiatry · 2026Pooled it
- Reconsidering evidence for psychedelic-induced psychosis: an overview of reviews, a systematic review, and meta-analysis of human studies.Molecular psychiatry · 2025Pooled it
- Pairwise genetic meta-analyses between schizophrenia and substance dependence phenotypes reveals novel association signals with pharmacological significance.Translational psychiatry · 2022Pooled it
- Transition of Substance-Induced, Brief, and Atypical Psychoses to Schizophrenia: A Systematic Review and Meta-analysis.Schizophrenia bulletin · 2020Pooled it
- Comparative efficacy of aripiprazole and paliperidone to treatment-as-usual in managing stimulant-induced psychosis: a 24-month randomized controlled trial.Frontiers in pharmacology · 2026Trial
- "Cannabis Green Wave" versus "Nicotine Freeze": the regulatory paradox of cannabis liberalization and nicotine prohibition.Harm reduction journal · 2026Article
- A call for action: Closing the evidence gap in management of stimulant-induced psychosis.Addiction (Abingdon, England) · 2026Article
- Comparative Clinical Trajectories Across Cannabis-Related and Nonsubstance-Related Psychoses.Acta psychiatrica Scandinavica · 2026Article
- Predictors of conversion to psychosis and mortality in first-episode substance-induced psychosis: a nationwide register-based study in South Korea.Schizophrenia (Heidelberg, Germany) · 2026Article
- From dust till dawn: patterns, motives, and risks of using smokable synthetic cathinones.Harm reduction journal · 2026Observational
- Substance-Specific Treatment Responses and Resistance Patterns in Induced Psychoses: A Scoping Review of Antipsychotic Efficacy.Healthcare (Basel, Switzerland) · 2025Review
- Symptom severity and cognitive performance in patients with substance induced psychotic disorder and schizophrenia: a cross-sectional comparative study.Schizophrenia research. Cognition · 2025Article
- Psychopathic Traits Associate With Later Schizophrenia.Acta psychiatrica Scandinavica · 2025Article
- Exploring the implications of case selection methods for psychiatric molecular genetic studies.Molecular psychiatry · 2025Article
- Alcohol-induced psychosis and delirium tremens: a comparison with alcohol dependence on demographic characteristics, mortality, and morbidity.BMC psychiatry · 2025Article
- Frequency and patterns of substance-induced psychosis in persons with concurrent mental health and substance use disorders during the COVID-19 pandemic: A Norwegian register-based cohort study.European psychiatry : the journal of the Association of European Psychiatrists · 2024Article
- Psychotic symptoms associated increased CpG methylation of metabotropic glutamate receptor 8 gene in Chinese Han males with schizophrenia and methamphetamine induced psychotic disorder: a longitudinal study.Schizophrenia (Heidelberg, Germany) · 2024Article
- Substance-Induced Psychiatric Disorders, Epigenetic and Microbiome Alterations, and Potential for Therapeutic Interventions.Brain sciences · 2024Review
- DEMOGRAPHIC PROFILE, SUBSTANCE USE TRENDS AND ASSOCIATED PSYCHOTIC DISORDERS AMONG VETERANS WITH MENTAL HEALTH CONDITIONS: A RETROSPECTIVE COHORT STUDY OF US VETERANS.ASEAN journal of psychiatry · 2024Article
- Lymphocyte-related ratios in methamphetamine-induced psychotic disorder in Taiwan, comparing with patients with schizophrenia.Addiction biology · 2024Article
9 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDespite the clinical importance of substance-induced psychosis (SIP), few studies have examined the course of this condition after its acute manifestation.
objectiveTo investigate the rate of SIP conversion to a schizophrenia spectrum disorder and the length of follow-up needed to catch the majority of these patients whose diagnoses change. In addition to the conversion rate and pattern, we wanted to look for possible related factors.
methodUsing the nationwide Finnish Hospital Discharge Register, we followed all patients (N = 18,478) since their first inpatient hospital admission with a diagnosis of SIP (codes 2921 and 2928 in DSM-III-R and codes F10-F19 in ICD-10 with a third digit of 4, 5, or 7) between January 1987 and December 2003 in Finland. Patients (mean age = 43.7 years, standard deviation = 13.5 years) were followed until first occurrence of schizophrenia spectrum disorder, death, or the end of December 2003, whichever took place first. Conversions of discharge diagnoses into schizophrenia spectrum disorders (codes 2951-2959 and 2971 in DSM-III-R and codes F20, F22, and F23 in ICD-10) were recorded at follow-up.
resultsEight-year cumulative risk to receive a schizophrenia spectrum diagnosis was 46% (95% CI, 35%-57%) for persons with a diagnosis of cannabis-induced psychosis and 30% (95% CI, 14%-46%) for those with an amphetamine-induced psychosis. Although alcohol-induced psychosis was the most common type of SIP, 8-year cumulative risk for subsequent schizophrenia spectrum diagnosis was only 5.0% (95% CI, 4.6%-5.5%). No differences were detected with regard to gender, except for amphetamine-induced psychosis, which converted into a schizophrenia spectrum disorder significantly more often in men (P = .04). The majority of conversions to a schizophrenia spectrum diagnosis occurred during the first 3 years following the index treatment period, especially for cannabis-induced psychosis.
conclusionSubstance-induced psychotic disorders predict schizophrenia spectrum disorders to a greater extent than previously thought. The intensity of clinical attention focused on substance-induced psychotic disorders should be increased.
Indexed as
Identifiers
23419236What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.